Salivary gland tumors are rare set of cancers accounting for less than 5% of all head and neck cancers. Of the various histologies salivary duct carcinomas are aggressive tumors with no standard of care management protocol. Several phase 1 and phase 2 studies of systemic therapy and targeted therapy in these tumors show minimal response rate. We present a case of metastatic salivary duct carcinoma, in whom next generation sequencing detected a targetable mutation in AKT1 gene and was started on everolimus with a stable disease over next 5 months.